Medtech firm Baxter Q3 profit beats on Infusion Systems growth; raises 2026 outlook
Overview
Global medtech firm's Q3 revenue grew 5% yr/yr, beating analyst expectations
Adjusted EPS for Q3 was down 16% yr/yr but beat analyst expectations
Company raised full-year 2026 sales and adjusted EPS outlook
Outlook
Baxter raises 2026 reported sales growth outlook to 4%-5% from 3%-4%
Company now sees 2026 organic sales growth of 3%-4%, up from 2%-3%
Baxter expects 2026 adjusted EPS of $2.05-$2.15, up from $1.95-$2.15
Result Drivers
INFUSION SYSTEMS & IV SOLUTIONS - Co said growth in Infusion Systems, Drug Compounding and IV Solutions drove Medical Products & Therapies segment sales
CARE & CONNECTIVITY SOLUTIONS - Co attributed Healthcare Systems & Technologies segment growth to demand for Global Surgical Solutions, Patient Support Systems and Front Line Care
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $2.98 bln | $2.91 bln (12 Analysts) |
Q3 Adjusted EPS | Beat | $0.58 | $0.52 (13 Analysts) |
Q3 Net Income | $294 mln |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 13 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Baxter International Inc. is $27.00, about 6% above its October 28 closing price of $25.46
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months ago
Reuters Recommended Reads
Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption
Oct 28 - Align Technology Q3 revenue slightly beats estimates
Oct 28 - Boston Scientific warns of tough 2027 on China pricing, heart-device weakness
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)